We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

S2k-Leitlinie AIT 2022

S2k-Leitlinie zur Allergen-Immuntherapie (deutsch)
S2k-Guideline on allergen immunotherapy (englisch)

Richtige Zitation: Pfaar O, et al. Guideline on allergen immunotherapy in IgE-mediated allergic diseases. Allergol Select. 2022; 6: 167-232. DOI 10.5414/ALX02331E

Die hier gelisteten Tabellen (zusätzliche Direktlinks am Ende der Seite) ergänzen die oben genannte Leitlinie mit halbjährlich aktualisierten Präparate-spezifischen Informationen.

Frühblüher-/Birkenpollen AIT-Präparate (tree/birch pollen therapy allergens)

Gräserpollen AIT-Präparate (grass pollen therapy allergens)

Hausstaubmilben AIT-Präparate (house dust mite therapy allergens)

Weiterführende Materialien:

Stand: 19.07.2023

Eine Aktualisierung der Tabelle(n) zur AIT ist im sechsmonatigen Abstand geplant.